Notice: Wiley Online Library will be unavailable on Saturday 30th July 2016 from 08:00-11:00 BST / 03:00-06:00 EST / 15:00-18:00 SGT for essential maintenance. Apologies for the inconvenience.
Potential conflict of interest: Nothing to report.
This work received grants from the Bundesministerium für Bildung und Forschung (BMBF), “Innovative Therapieverfahren,” grant number 01GU0702, the Landesstiftung Baden Württemberg and financial support from the Vision 7 GmbH.
The data presented in this study is consistent with the recent publication of Yan et al. describing sodium taurocholate cotransporting polypeptide (NTCP/SLC10A1) as a specific receptor for HBV and HDV infection. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. elife 2012;1:e00049.
Chronic infection with the human hepatitis B virus (HBV) is a global health problem and a main cause of progressive liver diseases. HBV exhibits a narrow host range, replicating primarily in hepatocytes. Both host and hepatocyte specificity presumably involve specific receptor interactions on the target cell; however, direct evidence for this hypothesis is missing. Following the observation that HBV entry is specifically blocked by L-protein-derived preS1-lipopeptides, we visualized specific HBV receptor/ligand complexes on hepatic cells and quantified the turnover kinetics. Using fluorescein isothiocyanate-labeled, myristoylated HBV preS1-peptides we demonstrate (1) the presence of a highly specific HBV receptor on the plasma membrane of HBV-susceptible primary human and tupaia hepatocytes and HepaRG cells but also on hepatocytes from the nonsusceptible species mouse, rat, rabbit and dog; (2) the requirement of a differentiated state of the hepatocyte for specific preS1-binding; (3) the lack of detectable amounts of the receptor on HepG2 and HuH7 cells; (4) a slow receptor turnover at the hepatocyte membrane; and (5) an association of the receptor with actin microfilaments. The presence of the preS1-receptor in primary hepatocytes from some non-HBV-susceptible species indicates that the lack of susceptibility of these cells is owed to a postbinding step. Conclusion: These findings suggest that HBV hepatotropism is mediated by the highly selective expression of a yet unknown receptor* on differentiated hepatocytes, while species specificity of the HBV infection requires selective downstream events, e.g., the presence of host dependency or the absence of host restriction factors. The criteria defined here will allow narrowing down reasonable receptor candidates and provide a binding assay for HBV-receptor expression screens in hepatic cells. (HEPATOLOGY 2013)
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.
Chronic hepatitis B is a global medical problem caused by the human hepatitis B virus (HBV). About 350 million people are persistently infected and need therapeutic treatment to reduce the risk of developing liver cirrhosis and HCC.1 Since the currently approved medications are mostly noncurative, novel therapeutic strategies are needed.2
HBV, the prototypic member of the hepadnavirus family, is a 42 nm, enveloped, partially double-stranded DNA virus with a restricted host range and an extraordinary tropism to infect the parenchymal liver cells of its host.3 Since HBV properly assembles after transfection with genomic HBV DNA of even nonhepatic cells, the specificity for hepatocytes must be related to an early infection event. One of the proposed restricted steps might be the lack of a hepatocyte-specific receptor. However, this hypothesis needs to be proven.
The envelope of HBV consists of proteins termed large (L), middle (M), and small (S) protein. They are encoded in one open reading frame and share the C-terminal S-domain which provides four trans-membrane helices4 and is probably involved in fusion.5 In addition to the S-domain, the M-protein contains an extension of 55 amino acids called preS2. The L-protein has a further N-terminal extension termed preS1. The preS1-domain of L- becomes N-terminally myristoylated and plays a key role in HBV entry into hepatocytes.6
Due to the previous limitation to primary human (PHHs) and primary tupaia belangeri hepatocytes (PTH) and HepaRG cell lines as the only in vitro HBV infection systems, receptor recognition and the mechanism of virus entry and membrane fusion are just about to be understood. Using HepaRG cells7 and primary PTH,8 heparin sulfate proteoglycans (HSPG) were identified as inevitable to initiate HBV infection.9, 10 Since HSPG interaction cannot explain HBV hepatocyte specificity, it is supposed an essential but not very specific step.
Using recombinant HBV and hepatitis delta virus (HDV) as a surrogate system to study HBV entry, essential infectivity determinants within the envelope proteins have been identified: (1) N-terminal myristoylation of L is mandatory for infectivity.11, 12 (2) Consecutive removal or insertion of short sequences in the N-terminal 75 amino acids (genotype D) of the preS1-domain abrogates infection.13, 14 Deletions and mutations introduced C-terminally of amino acid 75 including elimination of the M-protein and randomization of the preS2-domain within the L-protein had almost no influence on infectivity.15, 16 (3) Besides preS1, another essential element of HBV/HDV infectivity has been assigned to the antigenic loop (AGL) of the S-domain.17 Replacement of cysteine residues in the AGL rendered HDV and HBV (Yi Ni, unpubl. results) noninfectious. Since some of these cysteines (e.g., Cys-124) participate in intramolecular disulfide bonds, the sensitivity against reducing agents hints at the involvement of disulfide-bridge rearrangements during virus entry.18 Since only L-protein containing SVPs are able to bind hepatocytes from Tupaia belangeri the S-protein/domain is probably not essential for hepatocyte-specific binding.19
Consistent with the results of the mutational analyses, HBV preS1-derived lipopeptides, mimicking the myristoylated N-terminal preS1-infectivity domain, efficiently inhibit HBV and HDV infection of HepaRG cells, PHH, and PTH.7, 20-23 The activity of the peptides requires myristoylation and the integrity of an internal sequence (9-NPLGFFP-15) which is highly conserved between primate hepadnaviruses.21 Since their inhibitory effect remains for several hours after preincubation they probably inactivate a cellular receptor.24
In the present study we used fluorescently labeled, myristoylated HBVpreS1-peptides to analyze the presence and turnover kinetics of this HBVpreS1-specific receptor on hepatocytes from different species. We investigated whether receptor expression coincides with the species specificity of HBV and demonstrate highly specific binding of the preS1-lipopeptide to permissive cells (PHH, PTH, HepaRG). Unexpectedly, we detected specific binding to hepatocytes from non-susceptible species such as mouse, rat, rabbit, and dog, but not pig, cynomolgus, or rhesus monkey. Expression of a functional HBVpreS1-receptor was associated with the differentiation state of the hepatocyte: No binding was observed in undifferentiated HepaRG cells or dedifferentiated PMH and PHH. HepG2 and HuH7 cells were unable to bind the peptide even after dimethyl sulfoxide (DMSO)-induced differentiation. Kinetic studies demonstrated a slow turnover and a constrained lateral movement of the receptor complex at the plasma membrane (PM), possibly due to a cytoskeleton interaction.
Peptides were produced by solid phase synthesis employing the Fmoc/tBu strategy with O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate; (HBTU) / N,N-Diisopropylethylamine (DIPEA) activation in an Applied Biosystems 433A peptide synthesizer. Fluorescein isothiocyanate (FITC; Applichem) was coupled to the ϵ-amino group of an introduced D-lysine at position 49. Alternatively, Atto-565-maleimide (Fluka) was linked to a cysteine at the same position. Reversed phase high-performance liquid chromatography (HPLC) was carried out as described (Schieck et al.25). The identity of the peptides was verified by mass spectrometry. Stock solutions (500 μM) of the peptides in 2% DMSO were prepared, diluted with the appropriate medium, and added to the cells at the indicated concentrations.
Preparation and Cultivation of Primary Hepatocytes and Cell Lines.
PHH were cultivated in serum-free medium as described.26 Tissue samples from liver resections were obtained from patients undergoing partial hepatectomy. Experimental procedures were performed according to the guidelines of the charitable state controlled foundation HTCR (Human Tissue and Cell Research), with the informed patient's consent approved by the local Ethical Committee of the University of Regensburg. PMH were prepared by a two-step standard perfusion protocol using a 2-mM EGTA-containing buffer, followed by a treatment with 3.3 mg/mL collagenase type IV (Sigma-Aldrich).27 Parenchymal cells were enriched through resuspension and centrifugation of the cells in a Percoll solution with a density of 1,063 g/mL. Cryopreserved hepatocytes were bought from Celsis (rabbit, dog, cynomolgus monkey, rhesus monkey, and pig) or BD Gentest (rat and cynomolgus monkey). Cryopreserved PTHs were a kind gift of Maura Dandri (Hamburg). HuH7 and HepG2 cell lines were cultivated in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal calf serum (FCS), L-glutamine (2 mM), penicillin (50 U/mL), and streptomycin (50 μg/mL). HepaRG cells were cultivated as described.7 To induce differentiation, HuH7 and HepG2 cells were treated for 14 days with 0.5% DMSO; dedifferentiation of PMH and PHH was induced by growth in DMSO-free medium for up to 8 days.
Binding Assays with Fluorescently Labeled HBVpreS-peptides.
Binding experiments were performed in supplemented Williams E medium as described above. For PHH, medium was complemented with 50 μM hydrocortisone and 5 μg/mL insulin. Experiments with primary hepatocytes were carried out either on day 1 after plating (microscopy) or immediately after thawing (flow cytometry). HepaRG cells were tested on day 5 after seeding, or 2 weeks after DMSO-induced differentiation. Cells were incubated at 37°C with the appropriate labeled peptide in medium. Binding competition was carried out by coincubation of HBVpreS/2-48myr-K-FITC with an excess of unlabeled HBVpreS/2-48myr.
For infection inhibition, HepaRG cells were preincubated for 30 minutes with peptide and inoculated with a 1:20 dilution of a polyethylene glycol (PEG)-precipitated (50- to 100-fold enrichment) HepG2.2.15/HepAd38-derived virus stock (16 hours at 37°C)7 in medium containing 250 nM peptide and 4% PEG 8000 (Sigma-Aldrich). Cells were repeatedly washed and cultivated for up to 2 weeks. To quantify HBV replication, medium was collected from day 8 to 13 post infection and secreted HBeAg was determined by enzyme-linked immunosorbent assay (ELISA (AxSym, Abbott)).
Primary hepatocytes were grown on coverslips, coated with 0.1 mg/mL collagen (Cell Systems). After incubation with peptide at 37°C, cells were washed in phosphate-buffered saline (PBS), fixed (4% paraformaldehyde [PFA]), and mounted in DAPI-containing mounting medium (VectaShield). Microscopy was performed on a Perkin Elmer spinning disk confocal microscope, using a 60× WI (NA 1.2) or 100× oil (NA 1.4) objective, a Hamamatsu C9100-50 camera, and the software Volocity (Perkin Elmer). Quantification of peptide binding was achieved by measurement of the gray values in 60 (Fig. 5A) or 50 (Fig. 5B) circular selections in 3 or 10 representative pictures using ImageJ (NIH, Bethesda, MD). To analyze fluorescence recovery after photobleaching (FRAP), PMH were grown on collagen-coated chambered coverglass (LabTek). Cells were incubated with 400 nM HBVpreS/2-48myr-C-Atto565, diluted in Leiboviz (L-15) phenol red-free medium for 1 hour at 37°C, washed, and supplied with fresh L-15. As a control, cells were stained with 5 μL/mL Vybrant DiI (Invitrogen). Live cell microscopy at 37°C was performed in a heated chamber. Bleaching was achieved using the 568 nm laser, and recovery of fluorescence was monitored for 30 seconds with a frequency of 2 frames per second.
The 4 × 105/mL freshly prepared or cryopreserved primary hepatocytes were incubated for 30 minutes at room temperature with 200 nM of the respective peptide. After washing (PBS) flow cytometry was performed using a FACS Calibur and the software Cell Quest Pro (Becton-Dickinson). Competition of binding was performed with a 100-fold excess of unlabeled HBVpreS/2-48myr or control peptides (HBVpreS/2-48myr(D11,13) and HBVpreS/1-48). Cell viability was assessed by propidium iodide. To exclude unspecific binding caused by nonparenchymal cells, hepatocyte preparations were controlled by uptake of acLDL (10 μg/mL for 2 hours at 37°C), a marker for endothelial cells.
Fluorescently Labeled HBVpreS/2-48myr Specifically Binds to the PM of Hepatic HepaRG Cells.
Myristoylated HBV-preS1 lipopeptides inhibit HBV infection of HepaRG cells.21 To investigate specific receptor-interaction, we synthesized a fluorescently labeled variant of HBVpreS/2-48myr (Fig. 1A) and performed binding assays with HepaRG cells. Cosynthetic coupling of one FITC-moiety per molecule HBVpreS/2-48myr-K-FITC was accomplished by introduction of a lysine at position 49. As a control, we synthesized a mutant lipopeptide in which the L-leucine at position 11 and the L-phenylalanine at position 13 were replaced by the respective D-enantiomers (HBVpreS/2-48myr(D11,13)-K-FITC). A second control peptide comprised the wildtype sequence but lacked the N-terminal myristoyl moiety (HBVpreS/1-48-K-FITC). Both peptides are inactive (HBVpreS/2-48myr(D11,13)) or drastically impaired in inhibitory activity (HBVpreS/1-48).21 To ensure that the K-FITC-residue had no effect on the inhibitory activity, we tested HBVpreS/2-48myr-K-FITC in comparison to the nonlabeled HBVpreS/2-48myr in an infection inhibition assay (Fig. 1B). HBVpreS/2-48myr-K-FITC inhibited HBV infection in PHH like HBVpreS/2-48myr, as measured by secreted HBeAg. HBVpreS/2-48myr(D11,13)-K-FITC was inactive, confirming the requirement of the 9-NPLGFFP-15 sequence. HBVpreS/1-48-K-FITC showed only marginal activity.
To examine whether the differences in infection inhibition reflect specific binding properties to susceptible cells, we incubated differentiated HepaRG cells with the three peptides (200 nM) and analyzed cell association by confocal microscopy. As depicted in Fig. 1C, HBVpreS/2-48myr-K-FITC was localized at the PM of HepaRG cells (upper right). Incubation of cells with HBVpreS/2-48myr(D11,13)-K-FITC (lower left) or HBVpreS/1-48-K-FITC (lower right) did not result in significant PM staining, demonstrating the dependency of binding on the sequence integrity and the presence of the myristic acid. The specific peptide signal could clearly be discriminated from the punctuated cellular autofluorescence detected in the absence of peptide (upper left). HBVpreS/2-48myr-K-FITC binding was observed only in the hepatic clusters of HepaRG cells but not in biliary cells (data not shown).
HBVpreS/2-48myr-K-FITC Specifically Binds PHH and PTH.
Besides HepaRG cells, HBV infects PHH28 and PTH8 and is blocked by acylated HBVpreS-derived lipopeptides.20, 24 We therefore tested PHH and PTH for their ability to bind HBVpreS/2-48myr-K-FITC. We detected a sequence-specific and myristoyl-dependent association of the wildtype but not the control peptide with the PM of PHH (Fig. 2A). Specific binding of HBVpreS/2-48myr-K-FITC to PHH could also be detected in suspended cells by flow cytometry (Fig. 2B). Significant binding, visible by a shift of the cell population towards an approximately 10-fold higher fluorescence signal, was observed only for cells incubated with HBVpreS/2-48myr-K-FITC, but not with HBVpreS/2-48myr(D11,13)-K-FITC (Fig. 2B, dark green line versus orange line). Binding was prevented by an excess of the nonlabeled peptide HBVpreS/2-48myr (blue line) but not with the respective mutant HBVpreS/2-48myr(D11,13) (red line). This substantiates the high specificity of HBVpreS-receptor interaction in PHH. Consistently, PTH bound HBVpreS/2-48myr-K-FITC with comparable efficacy as PHH. Again, binding was prevented by unlabeled HBVpreS/2-48myr but not by the mutant HBVpreS/2-48myr(D11,13) (Fig. 2C).
Binding of HBVpreS/2-48myr-K-FITC Is Not Restricted to HBV-Susceptible Hepatocytes.
To investigate if HBVpreS1-receptor expression is restricted to hepatocytes from HBV susceptible hosts, we performed binding studies using PMH that are not susceptible to HBV infection.29 Unexpectedly, we observed the same sequence specific and myristoyl-dependent binding of HBVpreS/2-48myr-K-FITC to the PMH surface as for PHH, PTH, and HepaRG cells (Fig. 3A). Specific binding to PMH was confirmed by flow cytometry (data not shown). Binding was also detected in primary rat hepatocytes (PRH) (Fig. 3B). Again, excess of unlabeled HBVpreS/2-48myr reduced the fluorescence to background level (blue line), whereas coincubation with HBVpreS/2-48myr(D11,13) had no effect (Fig. 3B, red line). Accordingly, an HBVpreS1-receptor is present on the hepatocytes of mice and rats. We extended this analysis and tested HBVpreS-peptide binding to primary hepatocytes from rabbits, dogs, cynomolgus monkeys, rhesus monkeys, and pigs. As depicted in Fig. 3C, we found specific binding of HBVpreS/2-48myr-K-FITC to rat, rabbit, and dog hepatocytes but surprisingly not to hepatocytes from cynomolgus and rhesus monkey, despite their closer evolutionary relation to humans. Binding was also not observed on pig hepatocytes. Thus, differentiated hepatocytes from some HBV nonsusceptible species do express the HBVpreS-specific receptor (mouse, rat, dog, and rabbit), while others do not (pig, cynomolgus, and rhesus monkey), indicating that a step downstream specific preS-binding must restrict HBV/HDV-infection in these species.
The susceptibility of HepaRG cells to HBV infection depends on a differentiated state of the cells.7, 30 Moreover, PHH lose their susceptibility to HBV when DMSO is withdrawn from the medium.31-34 In order to test if this correlates with the presence of the HBVpreS-receptor we analyzed undifferentiated (5 days after seeding) and differentiated HepaRG cells (28 days after seeding, including a 2-week DMSO treatment) for their ability to bind HBVpreS/2-48myr-K-FITC. As seen in Fig. 4A (upper panel, left), HBVpreS/2-48myr-K-FITC did not stain the PM of undifferentiated cells, whereas binding was seen after differentiation (lower panel, left). This implies a cell state-dependent induction of HBVpreS/2-48myr-receptor expression during HepaRG-differentiation. Accordingly, we investigated whether dedifferentiation of binding competent primary hepatocytes result in an opposite effect. We cultivated PMH in the absence of DMSO and followed their ability to bind HBVpreS/2-48myr-K-FITC over time (Fig. 4A, right panels). While freshly isolated PMH specifically accumulated the peptide at the PM, hepatocytes from the same preparation lost their ability to bind HBVpreS/2-48myr-K-FITC within a few days of cultivation. Loss of binding could be prevented by addition of DMSO (data not shown). This correlates with the fact that PHH lose their susceptibility for HBV during several days of cultivation in the absence of DMSO.28 Thus, expression of an HBVpreS-receptor is linked to pathways controlling the differentiation state of hepatocytes.
To investigate whether HuH7 and HepG2 express detectable amounts of the HBVpreS-receptor following DMSO-induced differentiation, we performed binding experiments with these cells under differentiation conditions. As shown in Fig. 4B (upper panel) dividing cultures of HuH7 and HepG2 cells showed no significant binding of HBVpreS/2-48myr-K-FITC. Cultivation in the presence of 0.5% DMSO for 2 weeks did not render the cells competent for HBVpreS/2-48myr-K-FITC-binding (Fig.4C, lower panels). Nonhepatoma cell lines with (293T, CHO-K1) or without a GAG-matrix (CHO-pgs745 cells) were also refractory for peptide binding (data not shown). This excludes a direct interaction with GAGs, a conclusion that was strengthened by the observation that binding of HBVpreS/2-48myr-K-FITC cannot be inhibited by heparin and suramin (Fig. 8A).
Kinetics of the HBVpreS-Receptor Complex Formation and Stability.
To obtain insight into the kinetics of the HBVpreS-receptor complex-formation and its stability at the hepatocyte surface, we performed a time course of peptide-binding and release from the surface of PHH and PMH. As shown in Fig. 5A, association of HBVpreS/2-48myr-K-FITC with the PM proceeds rapidly. One minute after incubation of PHH with the peptide, the typical rim-like staining of the cell is detectable. The signal increases within ∼20 minutes and remains virtually constant, indicating equilibrium. To examine kinetics of the peptide-receptor complex at the PM we incubated HBVpreS/2-48myr-K-FITC with PMH for 4 hours, removed the unbound peptide, and followed the disappearance of the membrane associated receptor/peptide complex for the duration of 24 hours at 37°C. Remarkably, fluorescence at the PM was still detectable 20 hours after removal of free peptide (Fig. 5B), indicating a very slow dissociation of the peptide from the receptor and a low turnover rate of the surface receptor. Quantification of the fluorescence revealed an approximate half-life of the peptide-receptor complex at the surface of PMH hepatocytes of about 11 hours (assuming that the FITC-label remains peptide associated). This is consistent with the in vivo half-life times in mice (Schieck et al.25).
To approximate the binding constant of the complex we incubated PMH with increasing concentrations of the wildtype and the mutant peptide and quantified cell-associated fluorescence by flow cytometry. HBVpreS/2-48myr-K-FITC, but also the mutant HBVpreS/2-48myr(D11,13)-K-FITC showed a concentration-dependent increase of cell-associated fluorescence (Fig. 6A). However, the binding curves differed considerably at concentrations below 400 nM. While the wildtype peptide showed significant binding, the mutant peptide was barely associated with the cells. At higher concentrations (400 nM to 3.2 μM), a linear increase of cell-associated fluorescence was observed for both peptides. Since non-myristoylated HBVpreS/1-48-K-FITC did not exhibit significant cell association even at the highest concentration (3.2 μM), we conclude that binding of the mutant peptide is driven by a myristoyl-mediated, unspecific PM-interaction. By subtraction of the values from nonspecific HBVpreS/2-48myr(D11,13)-K-FITC-binding from the signal of HBVpreS/2-48myr-K-FITC-binding we obtained a specific saturation binding curve (Fig. 6B). To estimate the dissociation constant KD of the complex, we plotted the ratio of the concentrations of bound ligand/free ligand against the fluorescence intensity (by Scatchard plot, Fig. 6C). Assuming a first-order binding kinetics, we obtained a KD of ∼67 nM at room temperature. This value neglects a possible turnover of the receptor and the peptide (by e.g., endocytosis or peptide degradation).
HBVpreS-Receptor Complex on Hepatocytes Shows No Detectable Lateral Movement.
We sublocalized the peptide-receptor complex on the cell surface and analyzed its ability to laterally move within the membrane by using laser scanning confocal live cell imaging. To quantity the dynamics of peptide-associated fluorescence we photobleached a region within the focal plane of the PM of PMH and measured fluorescence recovery over time (FRAP). Instead of an FITC-labeled peptide we applied HBVpreS/2-48myr-C-Atto565, a peptide bearing the more photostable Atto565 fluorophore. As depicted in Fig. 7A (upper panel) the peptide-associated fluorescence was detectable at the microvilli of hepatocytes 4 seconds before photobleaching. No recovery was observed within 30 seconds after bleaching (right pictures). In contrast, carbocyanine DiI, which incorporates into the fluid-phase lipid bilayer, showed fluorescence recovery within 6 seconds (Fig. 7A, lower panel). Hence, the HBVpreS1-receptor complex does not show lateral movement within the PM. We further analyzed the sublocalization of the peptide at the PM of PRH by confocal microscopy. Following incubation with 200 nM HBVpreS/2-48myr-K-FITC, a Z-stack projection confirmed marginal staining in intracellular cell compartments (Fig. 7B). Since the lack of lateral movement of the peptide receptor complex indicates a possible association with the actin cytoskeleton we performed a colocalization experiment using HBVpreS/2-48myr-K-FITC (green) and Phalloidin-Alexa546, a specific label for F-actin (red). As depicted in Fig. 7C, a subpopulation of F-actin colocalized with the peptide, seen as yellow spots surrounded by peptide-clusters.
HBVpreS/2-48myr-K-FITC Binds to a Proteinacious Molecule, Independently of Glycosamino Glycans.
Since HBV and HDV infection are efficiently inhibited by highly sulfated agents like heparin and suramin, we tested whether they also interfere with peptide binding. As shown in Fig. 8A, HBVpreS/2-48myr-K-FITC binds PMH in the presence of 600 μg/mL heparin or 200 μg/mL suramin, concentrations that inhibit HBV and HDV infection. Thus, the peptide does not address glycosaminoglycans as a possible target. However, the HBVpreS-receptor complex on PMH was partially sensitive to the treatment with the two proteases trypsin or GluC, indicating a possible involvement of a proteinacious molecule in the recognition of the peptidic ligand.
Up to now there is only limited experimental evidence to explain two notable features of an HBV infection: (1) the restriction to infect only differentiated hepatocytes and (2) the species specificity, limiting HBV infections to humans and chimpanzees. We here tested the hypothesis if both aspects of HBV infection may be linked to a specific interaction of the N-terminal preS1-domain. We took advantage of a fluorescently labeled inhibitory preS1-lipopeptide (HBVpreS/2-48myr-K-FITC) (Fig. 1B), thus allowing visual tracing of the HBVpreS/receptor complex. HBVpreS/2-48myr-K-FITC associates within minutes to the PM of differentiated hepatocytes (Fig. 5) in a sequence- and myristoyl-dependent manner (Fig. 1C). In contrast to the control peptide, which displays only unspecific cell association via its fatty acid moiety, specific binding of HBVpreS/2-48myr-K-FITC was detectable with a calculated KD of 67 nM. Unexpectedly, binding was not restricted to HBV-susceptible cells like PHH, PTH, or HepaRG cells (Fig. 2) but was also evident in hepatocytes from mouse, rat, rabbit, and dog, although slight differences were observed (Fig. 3). A remarkable observation was the absence of specific receptor sites in hepatocytes from pigs, cynomolgus, and rhesus monkeys. Together with the in vivo data showing that cynomolgus monkeys fail to accumulate the HBVpreS peptide in the liver (Schieck et al.25), this suggests the lack of a functional HBV receptor in this species.
The species-specific binding capabilities determined in vitro strongly support the selective liver accumulation of only those peptides that are able to inhibit HBV infection (Schieck et al.25). Our finding that a number of HBV nonsusceptible hepatocytes bind the HBVpreS-peptide suggests that the refractiveness to infection of these cells is not caused by the absence of a binding competent receptor. Since rodent cells support appropriate assembly and secretion of HBV following transfection, the block of infection must be linked to a postbinding host factor activity (fusion) or related to a postfusion step (transport, DNA-repair), or both. These possibilities have to be analyzed in the future and will have important implications for the development of small animal models for HBV and HDV.
Tight and specific binding required both, the N-terminal myristoylation of the preS1-sequence, probably mediating close contact and correct positioning of the peptide at the hepatocyte membrane, and the integrity of a highly conserved central sequence motif 9-NPLGFFP-15 flanked by two short amino acid stretches. Binding occurs only in hepatic cells that either accomplished a highly differentiated state or are kept under conditions to stabilize such a state. HuH7 and HepG2 cell lines did not bind HBVpreS-lipopeptides, either in a dividing, asynchronous culture, or in a DMSO-treated differentiated state. This might explain their refractiveness against HBV/HDV infection. Since these cell lines are derived from liver tumors, it would stand to reason that during the transformation process of hepatocytes HBV receptor expression might get lost. Since the requirement for a resting state of the hepatocyte to uphold susceptibility to infection is a general feature of hepadnaviruses, it is possible that hepatocyte-specific binding of both, ortho- and avihepadnaviruses, is also mediated by their N-terminal preS-domains. It is noteworthy that a commonly accepted but rarely scrutinized observation already hinted at the possibility that HBV receptor expression is not limited to hepatocytes from human primates: The finding that Tupaia belangeri, a member of the scandentia, is susceptible to HBV and that infection of PTH is blocked by HBVpreS lipopeptides,20 suggested the existence of such an entry receptor in tupaias. Binding of the peptide to PTH (Fig. 2C) confirms this hypothesis.
Regarding the future clinical application of Myrcludex B, the lead substance of HBVpreS lipopeptides, a medically important finding was that the KD (∼67 nM) differed by a factor >50 from the median inhibitory concentration (IC50) determined in infection inhibition assays. This raises the question of whether we address the same molecule in these assays. However, the strong correlation of the inhibition activity of more than 25 peptide mutants21 with their ability to target the HBVpreS-receptor in vivo (Schieck et al.25) makes the assumption highly unlikely. We therefore hypothesize that partial occupation of binding-sites already functionally inactivates the receptor. Thus, HBV, like other enveloped viruses, may require a receptor multimerization. Blocking of a single subunit by the peptide might therefore be sufficient to perturb entry. Since we did not detect significant lateral movement of the peptide-receptor complex (Fig. 7), we further suggest receptor association with the actin microfilaments. The partial sensitivity of the receptor ligand complex against the two proteases trypsin and GluC (Fig. 8B) indicates a proteinacious nature.
While the myristoylated peptide binds to hepatocytes within minutes, only a minor fraction of HBV infects PHH within 12 hours. This discrepancy might be explained by a hidden N-terminal preS-domain of L-protein in the virion followed by an only slow transition from the viral into the PM of hepatocytes (Supporting Fig. 1). This probably occurs very close to or even within the hepatocyte surface. Thus, the peptide might be regarded as a constitutively active ligand.
Taken together, the characterization of the hepatocyte-specific preS-receptor complex will allow narrowing down reasonable receptor candidates, which is important with respect to the future development of immune-competent animal models of HBV.
We thank Martina Spille for excellent technical assistance, Christoph Leder for initial help with the flow cytometry studies, Thomas Müller for peptide synthesis, Maura Dandri for providing primary hepatocytes from Tupaia belangeri, and Alexander Alexandrov for stimulating discussions. We thank Ulrike Engel and Christian Ackermann from the Nikon Imaging Center, Heidelberg, for excellent technical support in microscopy. We thank Ralf Bartenschlager for continuous intellectual support.